文献速递泌尿与男性生殖病理

伴血管母细胞瘤成分的肾透明细胞癌临床病理分析

[Clinicopathological analysis of clear cell renal cell carcinoma with hemangioblastoma component].
PubMed 文献 · Zhonghua Bing Li Xue Za Zhi · 2021-01-01

该研究纳入2例伴血管母细胞瘤成分的肾透明细胞癌(ccRCC-HBc),分析其形态学、免疫组化及FISH检测TFE3、TFEB、VHL基因特征并复习文献。结果示两种成分相互移行,ccRCC区表达PAX8、CKpan、EMA等,HB样区表达α-inhibin、CD34,FISH均未检出TFE3/TFEB分离信号。结论认为该亚型罕见,确诊依靠临床病理及免疫组化,分子检测有助鉴别。

要点

  • ccRCC-HBc由ccRCC成分与血管母细胞瘤样成分相互移行构成。
  • 免疫组化ccRCC区PAX8、CKpan、EMA、CD10等阳性,HB样区α-inhibin、CD34阳性。
  • FISH检测TFE3、TFEB基因分离信号均为阴性(0/2),有助鉴别。

核心结论

  • ccRCC-HBc是ccRCC一种罕见的变异亚型,确诊依靠临床病理学与免疫组化,分子病理有助鉴别。
  • 治疗以手术切除为主,辅以化疗,必要时行靶向治疗。

研究设计与样本

  • 收集2015年9月和2016年3月福建省立医院手术切除标本及会诊病例共2例ccRCC-HBc。
  • 进行HE、免疫组化染色,FISH检测TFE3、TFEB及VHL基因,并进行文献复习。

主要发现

  • 2例均为女性,年龄分别为33和66岁,肿块大小4.0 cm和8.5 cm。
  • ccRCC成分约占肿瘤10%-20%,HB样成分约占60%-70%,两种成分相互移行。
  • ccRCC区瘤细胞PAX8、CKpan、EMA、波形蛋白、CD10、RCC、CAⅨ、P504s阳性。
  • HB样区域α抑制素、CD34、波形蛋白阳性,CD10弱阳性。
  • FISH未检测到TFE3、TFEB基因分离信号(0/2),例2未检测到VHL基因突变(0/1)。

关键数值与推荐

  • ccRCC成分占肿瘤约10%-20%,HB样成分占约60%-70%。
  • FISH检测TFE3、TFEB基因分离信号阴性为0/2,VHL基因突变阴性为0/1。

临床怎么用

  • 诊断需结合临床病理形态与免疫组化,必要时行分子病理检测以鉴别。
  • 治疗以完整手术切除为主,辅以化疗,条件允许时行靶向治疗。

局限性

  • 仅纳入2例,样本量小,结论需更多病例验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinicopathological features, differential diagnosis and molecular characteristics of clear cell renal cell carcinoma (ccRCC) with hemangioblastoma component (ccRCC-HBc). Methods: Two ccRCC-HBc cases diagnosed at Fujian Provincial Hospital in September 2015 and March 2016, respectively, were included. Their morphological, immunohistochemical and molecular features were analyzed, including fluorescence in situ hybridization (FISH) detection of TFE3, TFEB and VHL genes. Related literature was reviewed to reveal the characteristics of this tumor. Results: The two cases occurred in 2 women, aged 33 and 66 years, respectively. The maximum diameters of the tumors were 4.0 cm and 8.5 cm, respectively. Histologically, the ccRCC component, representing approximate 10%-20% of the neoplasm, while the tumor cells arranged in flaky, nested, and solid distribution. The tumor cells had conspicuous nucleoli, with rich thin-wall capillary network in the stroma. The hemangioblastoma-like component, representing approximate 60%-70% of the neoplasm, showed a rich capillary network of single-layered flat endothelial cells enclosing stromal cells. The latter cell type showed a pale or eosinophilic cytoplasm exhibiting occasional lipid droplets. Rare cell nuclei appeared enlarged, pleomorphic, or bizarre. The two components were intermingled with each other. Immunohistochemically, the tumor cells were positive for PAX8, CKpan, EMA, vimentin, CD10, RCC, CAⅨ, and P504s in ccRCC area; in another area, the tumor cells were positive for α-inhibin, CD34 and vimentin, while CD10 were weakly positive. Neither TFE3 or TFEB gene split signal was detected in the 2 cases (0/2), nor was VHL gene mutation in case 2 (0/1). Conclusion: ccRCC-HBc is an extremely rare entity of ccRCC. The diagnosis is mainly based on clinical and pathological characteristics, as well as immunohistochemistry. Molecular pathology is helpful for its differential diagnosis. The primary approach of treating ccRCC-HBc is complete surgical excision and chemotherapy. The targeted treatment is helpful if possible. 目的: 探讨伴血管母细胞瘤成分肾透明细胞癌[clear cell renal cell carcinoma (ccRCC) with hemangioblastoma(HB) component, ccRCC-HBc]的临床病理及分子学特征。 方法: 收集2015年9月和2016年3月福建省立医院手术切除标本及会诊病例共2例ccRCC-HBc,进行HE、免疫组织化学染色,荧光原位杂交(FISH)检测TFE3、TFEB及VHL基因,并进行文献复习。 结果: 2例女性,年龄分别为33和66岁,肿块大小4.0 cm和8.5 cm。病理组织学上2例肿瘤可见明确ccRCC区域,部分区呈血管母细胞瘤(HB)样表现,见增生的毛细血管,细胞多变,胞质透明、空泡样,两种成分相互移行。免疫表型上,ccRCC区瘤细胞呈PAX8、广谱细胞角蛋白(CKpan)、上皮细胞膜抗原(EMA)、波形蛋白、CD10、肾细胞癌标志物(RCC)、碳酸酐酶Ⅸ(CAⅨ)、P504s阳性;HB样区域α抑制素、CD34、波形蛋白阳性,CD10弱阳性。FISH均未检测到TFE3、TFEB基因分离信号(0/2),例2未检测到VHL基因突变(0/1)。 结论: ccRCC-HBc属于ccRCC一种罕见的变异亚型,确诊依靠临床病理学、免疫组织化学,必要时行分子病理检测有助鉴别。治疗以手术切除为主,并辅以化疗,必要时行靶向治疗。.

来源:Zhonghua Bing Li Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Huang HJ, Chen MJ, Li XO, et al. [Clinicopathological analysis of clear cell renal cell carcinoma with hemangioblastoma component]. Zhonghua Bing Li Xue Za Zhi. 2021. PMID: 33535303. doi:10.3760/cma.j.cn112151-20200527-00417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。